Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Momelotinib in Polycythemia Vera or Essential Thrombocythemia
2013-004105-11Phase 2Terminated
- Sponsor
- Gilead Sciences
- Start
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of mivavotinib in polycythemia vera (PV) and thrombocythemia (3 arms), sponsored by Gilead Sciences. Primary endpoint: Overall response rate (ORR). Started Jan 2014; status: terminated.
02
Drugs
mivavotinib
03
Conditions
polycythemia vera (PV)thrombocythemia
Beyond the preview
Go deeper on 2013-004105-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004105-11.